GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (LTS:0HA3) » Definitions » Price-to-Funds-From-Operations

Adverum Biotechnologies (LTS:0HA3) Price-to-Funds-From-Operations : (As of Jun. 09, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Adverum Biotechnologies Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Adverum Biotechnologies (LTS:0HA3) Business Description

Traded in Other Exchanges
Address
100 Cardinal Way, Redwood CIty, CA, USA, 94063
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.